This is partly in response to Michael's question about whether next year's earnings are a beat or a miss next week. I would guess it's a beat and that the news will be good about Dupixent sales. I think it's quite possible though that this rapid price in stock means that good earnings and sales are already baked into the cake and that we don't see much upside for awhile. Just guessing as usual.
the NEW ENGLAND JOURN. OF MEDICINE in last edition has two articles dedicated to role of ANGPTL3 in atherosclerosisl.In the article the drug Evinacumab is shown to be a potent inhibitor of ANGPTL3 and thus lowers cholesterol,hdl,and ldl. Interestingly Evinacumab is made by Regeneron. Anyone care to comment on the potential for this interesting new drug?
what can we do to make this board have informed comments, new information, pointed questions and answers and the like?
VALEANT ON MOVE MAY BE 10 TO 15% UP BY FEW DAYS..
Very up and down stock. Too risky to jump in.
Elle n'est pas si belle aujourd'hui comme moiselle bleu
this stock has been good to me this past week
dump is coming.. pump and dump.. 536 to 524 in a heartbeat today.. 520-460 in a couple of weeks.. just a trade to the fund managers no long term #$%$ they sucker the small investors with.
Okay, so we're 5% up 2 days in a row. What do you guys think for tomorrow? Up, down, stable?
why the massive drop with no news.. just a trade as I said bf.. does not trade on fundmentals or good news...
moiselle regeneron est en rouge aujourd'hui et j'aime bien ca
What the big jump?
these companies should be banned for cheating. People eat healthy and they don't need stupid medicines
Novartis eye drug works with fewer injections than rival
A Novartis drug to treat a leading cause of vision loss in people over 65 does not need to be injected as frequently as a rival medicine from Regeneron Pharmaceuticals to be effective, clinical trials showed on Tuesday.
Yahoo Finance Insights
REGN reached a new 52 Week High at 494.00
There probably is a rotation sector going on now and Celgene and Amgene have also risen. I think Regeneron goes up in the next year but back a bit overall in the next few weeks but if the lawsuit with Amgen hints toward a favorable outcome for Regeneron the stock is going to get another good run. It's kind of ridiculous though since the valuations are going to come from Dupixent and Eylea. The stock is going to get hit at some point when people realize that Eylea sales are going to dip with this Novartis development of a new MD drug.
AXSM = Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.